After getting master degree of Pharmaceutical Science at Univ. of Tokyo in 1978, I joined Daiichi Pharmaceutical as a research scientist of immunology. In 2004, I got a position of VP of a Research Institute covering immunology, oncology and infectious disease area at Daiichi (2004-2007) and Daiichi Sankyo (2007-2010). Then I moved to Daiichi Sankyo RD Novare as a Board member in 2010. I finished my career in a private pharmaceutical company in 2013, then got a position in National Institute of Biomedical Research in 2013 then moved to AMED (Japan Agency for Medical Research and Development) to support academic drug discovery research for transferring its achievement to industries. I have been a Science and Technology Advisor of AMED since 2018.

What I expect of LINK-J

Since LINK-J was established in 2016, its role as an accelerator for community construction in the field of life science in NIhonbashi area has been more important through lots of well-organized events etc. Recently LINK-J announced establishment of BSL-2 compatible rental labs in east of Tokyo-bay area close to Nihonbashi area, this new activity definitely results in expansion of business networks as well as human linkage. I expect LINK-J activities create new innovation in this area.

Message to LINK-J Special Members

I expect innovation will be created through construction of ecosystem as well as networks between different industries.